{
    "nctId": "NCT01519700",
    "briefTitle": "Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim",
    "officialTitle": "A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen\u00ae in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Chemotherapy Associated Neutropenia, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 218,
    "primaryOutcomeMeasure": "Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with histologically proven breast cancer, eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy\n2. Women \u2265 18 years of age\n3. Estimated life expectancy of more than six months\n\nExclusion Criteria:\n\n1. Previous or concurrent malignancy except non-invasive non-melanoma skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least ten years prior to study entry\n2. Any serious illness or medical condition that may interfere with safety, compliance, response to the products under investigation and their evaluation, e.g.:\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}